Certara Inc (CERT)

Currency in USD
7.15
-0.20(-2.72%)
Closed·
6.99-0.16(-2.24%)
·
CERT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.907.52
52 wk Range
6.0415.38
Key Statistics
Prev. Close
7.15
Open
7.31
Day's Range
6.9-7.52
52 wk Range
6.04-15.38
Volume
3.88M
Average Volume (3m)
2.61M
1-Year Change
-38.4682%
Book Value / Share
6.67
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CERT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.73
Upside
+36.07%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Certara Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

Certara Inc Company Profile

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Employees
1546

Certara Inc SWOT Analysis


Biosimulation Pionee
Certara leads in AI-assisted drug development, offering innovative solutions to streamline pharmaceutical R&D processes and reduce time-to-market for new therapies.
Financial Resilience
Explore Certara's robust financial performance, with Q1 2025 revenue up 10% YoY to $106M, exceeding analyst expectations despite industry challenges.
Strategic Positioning
Delve into Certara's strategic initiatives, including its non-animal testing solutions and Cloud platform development, aligning with key industry trends.
Valuation Insights
Analysts set price targets from $13 to $18, with Certara trading at 14x estimated 2025 EBITDA, potentially undervalued compared to peers.
Read full SWOT analysis

Certara Inc Earnings Call Summary for Q4/2025

  • Q4 revenue rose 3% YoY to $103.6M, exceeding forecasts; EPS of $0.09 missed estimates by 18%, falling from $0.15 in Q4 2024.
  • Software segment grew 10% YoY to $46.4M driven by AI adoption; services revenue declined 1% to $57.3M amid market pressures.
  • Stock dropped 1.67% premarket to $6.48, near 52-week low; shares down 46.6% over past year, though analysts suggest undervaluation.
  • New CEO Jon Resnick focuses on AI integration and operational excellence; FY 2026 guidance projects $0.13 EPS per quarter.
  • Company expects net income growth in 2026 with new AI-enhanced product launches; faces risks from competition and macro uncertainties.
Last Updated: 27/02/2026, 02:28 am
Read Full Transcript

Compare CERT to Peers and Sector

Metrics to compare
CERT
Peers
Sector
Relationship
P/E Ratio
−713.4x−0.2x−0.5x
PEG Ratio
−8.380.030.00
Price/Book
1.1x1.1x2.6x
Price / LTM Sales
2.7x1.3x3.2x
Upside (Analyst Target)
39.9%89.7%51.4%
Fair Value Upside
Unlock37.3%8.5%Unlock

Analyst Ratings

6 Buy
7 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 9.73
(+36.07% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Barclays
Hold8.00+11.89%-Downgrade06/03/2026
Citizens
Hold---Maintain03/03/2026
BMO Capital
Hold7.00-2.10%9.00Maintain27/02/2026
Craig-Hallum
Hold10.00+39.86%-Downgrade27/02/2026
Baird
Hold8.00+11.89%11.00Maintain27/02/2026

Earnings

Latest Release
Feb 26, 2026
EPS / Forecast
0.09 / 0.11
Revenue / Forecast
103.60M / 103.23M
EPS Revisions
Last 90 days

CERT Income Statement

People Also Watch

26.07
DOCS
-1.40%
12.52
QNST
+5.39%
29.26
RAMP
+2.09%

FAQ

What Is the Certara (CERT) Stock Price Today?

The Certara stock price today is 7.15 USD.

What Stock Exchange Does Certara Trade On?

Certara is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Certara?

The stock symbol for Certara is "CERT."

What Is the Certara Market Cap?

As of today, Certara market cap is 1.14B USD.

What Is Certara's Earnings Per Share (TTM)?

The Certara EPS (TTM) is -0.01.

When Is the Next Certara Earnings Date?

Certara will release its next earnings report on 11/05/2026.

From a Technical Analysis Perspective, Is CERT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Certara Stock Split?

Certara has split 0 times.

How Many Employees Does Certara Have?

Certara has 1546 employees.

What is the current trading status of Certara (CERT)?

As of 06/03/2026, Certara (CERT) is trading at a price of 7.15 USD, with a previous close of 7.15 USD. The stock has fluctuated within a day range of 6.90 USD to 7.52 USD, while its 52-week range spans from 6.04 USD to 15.38 USD.

What Is Certara (CERT) Price Target According to Analysts?

The average 12-month price target for Certara is 9.73 USD, with a high estimate of 15 USD and a low estimate of 7 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +36.07% Upside potential.

What Is the CERT Premarket Price?

CERT's last pre-market stock price is 6.99 USD. The pre-market share volume is 7,280.00, and the stock has decreased by -0.16, or -2.24%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.